二、被提名人任职资格符合下列法律、行政法规和部门规章以及公司规章的 要求: (一) 《中华人民共和国公司法》关于董事任职资格的规定; (二)《中华人民共和国公务员法》关于公务员兼任职务的规定(如适用); 江苏吴中医药发展股份有限公司 独立董事提名人声明与承诺 提名人江苏吴中医药发展股份有限公司(简称"江苏吴中"或"公司")董 事会,现提名 杜若英先生 为江苏吴中医药发展股份有限公司第十一届董事 会独立董事候选人,并已充分了解被提名人职业、学历、职称、详细的工作经历、 全部兼职、有无重大失信等不良记录等情况。被提名人已同意出任江苏吴中医药 发展股份有限公司第十一届董事会独立董事候选人(参见该独立董事候选人声 明)。提名人认为,被提名人具备独立董事任职资格,与江苏吴中医药发展股份 有限公司之间不存在任何影响其独立性的关系,具体声明并承诺如下: 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行政法规、部 门规章及其他规范性文件,具有 5年以上法律、经济、财务、管理或者其他履行 独立董事职责所必需的工作经验。 (三)中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-063 江苏吴中医药发展股份有限公司第十一届董事会 2024 年第二次临时会议（通讯表决）决议公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）第十一届董事会 2024 年第二次临时会议（通讯表决）通知于 2024 年 10 月 8 日以书面或电子邮件等形 式发出，会议于 2024 年 10 月 10 日以通讯表决方式在公司会议室举行，会议的 召开符合《公司法》和相关法律法规以及《公司章程》《董事会议事规则》的规 定。会议应到董事 7 人，实到董事 7 人。会议由董事长钱群山先生主持。经会议 审议，以通讯表决方式审议通过了如下决议： 一、审议通过了江苏吴中医药发展股份有限公司关于补选第十一届董事会 独立董事的议案 表决结果：7 票同意， 0 票弃权， 0 票反对。 该事项尚需提交公司股东大会审议。 二、审议通过了江苏吴中医药发展股份有限公司关于回购注销部分限制性 股票的议案 鉴于公司 2021 年限制性股票激励计划 ...

关于控股股东部分股份质押的公告 证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-059 江苏吴中医药发展股份有限公司 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 公司于 2024 年 9 月 30 日收到控股股东苏州吴中投资控股有限公司关于部分 股份质押的通知，具体情况如下： 一、股份质押基本情况 1、本次股份质押基本情况 | 股东 | 是否为 | 本次质押股 | 是否 | 是否 | 质押 | | 质押 | | | 占其所 | 占公司 | 质押融 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 控股股 | 数(股) | 为限 | 补充 | 起始日 | | 到期日 | | 质权人 | 持股份 | 总股本 | 资资金 | | | 东 | | 售股 | 质押 | | | | | | 比例 | 比例 | 用途 | | 苏州吴 中投资 控股有 | 是 | 9,650,000 ...

Investment Rating - The report maintains a "Cautious Recommendation" rating for the company [4]. Core Views - The company achieved a revenue of 1.207 billion yuan in H1 2024, representing a year-on-year increase of 9.62%, while the net profit attributable to the parent company was 24 million yuan, down 10.75% year-on-year [2]. - The medical beauty business shows strong profitability, with a gross margin of 82.9% for the AestheFill product, which was officially launched in April 2024 [2]. - The company is actively promoting the AestheFill sales, increasing the number of cooperative medical beauty institutions, and enhancing training for terminal doctors [2]. - The company is focusing on both independent research and external investments, particularly in upstream injection products [2]. Financial Performance Summary - For 2024, the company is expected to achieve a revenue of 2.781 billion yuan, with a growth rate of 24.2% [3]. - The net profit attributable to the parent company is projected to be 132 million yuan in 2024, reflecting a significant increase of 283.5% [3]. - The earnings per share (EPS) is forecasted to be 0.19 yuan for 2024, with a price-to-earnings (PE) ratio of 46 [3][5].

证券研究报告·公司点评报告·医疗美容 江苏吴中（600200） 2024 年半年报点评：艾塑菲快速放量，医美 业务高增可期 2024 年 08 月 29 日 买入（维持） | --- | --- | --- | --- | --- | --- | |------------------------------|----------|---------|--------|--------|--------| | 盈利预测与估值 [Table_EPS] | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业总收入（百万元） | 2026 | 2240 | 2794 | 3451 | 4204 | | 同比（ % ） | 14.12 | 10.55 | 24.75 | 23.50 | 21.83 | | 归母净利润（百万元） | (76.27) | (71.95) | 125.10 | 261.61 | 402.63 | | 同比（ % ） | (435.74) | 5.67 | 273.89 | 109.11 | 53.91 | | EPS- 最新摊薄（元 / 股） | (0 ...

一、审议通过了江苏吴中医药发展股份有限公司 2024 年半年度报告与报告 摘要 根据《证券法》的规定和《公开发行证券的公司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》（2021 年修订）的有关要求，公司监事会对 董事会编制的 2024 年半年度报告进行了审核，并发表意见如下： 证券代码：600200 证券简称：江苏吴中 公告编号：临2024-054 江苏吴中医药发展股份有限公司 第十一届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）第十一届监事会第二 次会议通知于 2024 年 8 月 16 日以书面或电子邮件等形式发出，会议于 2024 年 8 月 27 日在公司会议室举行。会议应到监事 3 人，实到监事 3 人。会议的召开 符合《公司法》和相关法律法规以及《公司章程》《监事会议事规则》的有关规 定。会议由监事会主席吴振邦先生主持，会议经过审议，以书面投票表决方式通 过了如下决议： （三）在公司监事会提出意见前，未发现参与 2024 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-055 江苏吴中医药发展股份有限公司关于非公开发行 募集资金 2024 年上半年存放与实际使用情况的专项报告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 1 号——规范运作》及相关 格式指引的要求，现将本公司非公开发行募集资金 2024 年上半年存放与实际使 用情况专项报告如下： 一、募集资金基本情况 (一)实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准江苏吴中实业股份有限公司非公开发 行股票的批复》(证监许可[2015]2084号)核准，本公司获准非公开发行不超过 4,538万股新股(以下简称"本次发行")。本次发行实际发行数量为41,046,070 股，发行对象为6名，发行价格为12.52元/股，募集资金总额513,896,796.40元(含 发行费用)。扣除发行费用合计人民币11,519,544.24元后，本次募集资金净额为 人民币502,377,252.16元，上述募集资金已于2015年9月 ...

根据上海证券交易所发布的上市公司分行业信息披露指引《上市公司行业 信息披露指引第六号——医药制造（2022 年修订）》及《关于做好主板上市公司 2024 年半年报报告披露工作的重要提醒》的相关要求，现将江苏吴中医药发展 股份有限公司（以下简称"公司"）主营业务 2024 年 1-6 月主要经营数据情况公 告如下： 1、2024 年 1-6 月，公司医美生科业务累计实现主营业务收入 8,011.96 万 元，较上年同期增长 7,725.24 万元，增长 2,694.30%，医美生科业务主营业务 毛利 6,640.74 万元，较上年同期增长 6,467.87 万元，增长 3,741.55%。 2、2024 年 1-6 月，公司医药业务累计实现主营业务收入 85,671.55 万元 （其中医药工业 31,968.93 万元，医药商业 53,702.62 万元），较上年同期下降 5,717.84 万元，下降 6.26%，医药业务主营业务毛利 27,191.64 万元，较上年同 期下降 1,528.86 万元，下降 5.32%。 证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-056 江苏吴中医药发 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-053 江苏吴中医药发展股份有限公司 第十一届董事会第二次会议决议公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）第十一届董事会第二 次会议通知于 2024 年 8 月 16 日以书面或电子邮件等形式发出，会议于 2024 年 8 月 27 日在公司会议室举行，会议召开方式为现场会议与通讯表决相结合的方 式。会议的召开符合《公司法》和相关法律法规以及《公司章程》《董事会议事 规则》的规定。会议应到董事 7 人，实到董事 7 人。本次会议由董事长钱群山先 生主持，公司监事会成员及高级管理人员列席了会议。会议经过讨论审议，以书 面投票表决方式通过了以下决议： 一、审议通过了江苏吴中医药发展股份有限公司 2024 年上半年总经理工作 报告 具体见公司于 2024 年 8 月 28 日在《中国证券报》《上海证券报》及上海证 券交易所网站上披露的《江苏吴中医药发展股份有限公司关于拟对外投资的公 告》。 表决结果：7 票同意 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 1,206,511,609.78, representing a 9.62% increase compared to CNY 1,100,632,396.63 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2024 was CNY 24,454,605.15, a decrease of 10.75% from CNY 27,400,649.23 in the previous year[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 10,592,858.96, showing a significant increase of 417.83% compared to CNY 2,045,607.36 in the same period last year[16]. - The net cash flow from operating activities for the first half of 2024 was CNY 152,541,110.24, a substantial recovery from a negative cash flow of CNY -121,910,233.58 in the previous year[16]. - Basic earnings per share for the first half of 2024 were CNY 0.034, down 10.53% from CNY 0.038 in the same period last year[17]. - The diluted earnings per share for the first half of 2024 were also CNY 0.034, showing a decrease of 10.53% compared to the previous year[17]. - The weighted average return on net assets for the first half of 2024 was 1.392%, a slight decrease from 1.502% in the same period last year[17]. Product Development and Market Position - The net profit attributable to shareholders after deducting non-recurring gains and losses increased significantly due to the launch of the AestheFill product, generating a gross profit of RMB 66.4074 million in the medical beauty sector[18]. - The AestheFill product received regulatory approval and was officially launched in mainland China on April 22, 2024, marking a significant milestone for the company[21]. - AestheFill holds a nearly 30% market share in the regenerative injection market in Taiwan, ranking first among similar products[22]. - The company is focusing on high-end injectable products and related biomaterials, with ongoing clinical registration for new products and preclinical research for others[21]. - The pharmaceutical segment includes a diverse range of products, with key offerings in antiviral, immune regulation, and oncology fields, contributing to a robust product pipeline[21]. Financial Position and Assets - The total assets at the end of the reporting period were CNY 4,122,333,961.76, a decrease of 4.73% from CNY 4,326,878,114.57 at the end of the previous year[16]. - The net assets attributable to shareholders at the end of the reporting period were CNY 1,775,653,086.00, reflecting a 1.81% increase from CNY 1,744,014,382.12 at the end of the previous year[16]. - The company's cash and cash equivalents at the end of the reporting period amounted to ¥1,677,359,133.94, up from ¥1,511,993,492.34 at the end of the first half of 2023, showing an increase of approximately 11%[106]. - The company's total current assets decreased to approximately ¥2,936,17 million from ¥3,001.22 million, a decline of about 2.17%[94]. - The company's total liabilities decreased to ¥2,287,166,240.49, down 10.8% from ¥2,565,434,062.87[96]. Research and Development - The R&D management structure was optimized, with a focus on both chemical and biological innovative drug development[35]. - The company has established a joint laboratory for recombinant human collagen formulations with China Pharmaceutical University and Nanjing Dongwan Biotechnology, enhancing its R&D capabilities[38]. - The company is focusing on the development of innovative drugs and medical devices, supported by favorable government policies aimed at accelerating the approval process for new products[30]. Market Trends and Industry Insights - In the first half of 2024, the pharmaceutical manufacturing industry in China achieved revenue of RMB 1,235.27 billion, a year-on-year decline of 0.9%[23]. - The market for hyaluronic acid-based dermal fillers in China was valued at RMB 6.4 billion in 2021, with a compound annual growth rate (CAGR) of 19.7% from 2017 to 2021, and is projected to reach RMB 19.6 billion by 2026, with a CAGR of 25.0%[24]. - The market for PLA/PCL-based dermal fillers in China reached RMB 1.45 billion in 2022, with a staggering CAGR of 259.4% from 2021 to 2022, and is expected to grow to RMB 11.52 billion by 2027, with a CAGR of 31.2% from 2025 to 2027[25]. Environmental Responsibility - The total emissions of chemical oxygen demand (COD) from the Suzhou Pharmaceutical Plant (Hedong) were 0.673 tons for the first half of 2024, well below the limit of 500 mg/L[66]. - The company has implemented measures to ensure that all emissions are within the regulatory standards, reflecting a commitment to environmental responsibility[65]. - The company has established a hazardous waste storage facility exceeding 500㎡, with all necessary preventive measures in place[68]. Risk Management - The company faces potential risks including industry policy risks, technology innovation risks, and customer credit risks, which could impact future profitability[50]. - The company plans to strengthen credit transaction management and risk management training to mitigate potential bad debt losses due to customer defaults[52]. - Rising costs of production factors, including raw materials and labor, pose a risk to operational costs, prompting the company to implement lean production practices[55]. Shareholder and Governance - The company committed to ensuring that the funds raised from the non-public offering will not be used for real estate and related businesses, adhering to regulatory requirements[75]. - The company has established a three-party supervision system for the use of raised funds, ensuring compliance with investment project disclosures[75]. - The company has no significant litigation or arbitration matters during the reporting period[76].